Wang Yunfeng, Zhang Yan, Liu Zhongguo, Li Qiuying, Jin Huijing
Department of Clinical Laboratory, Chengyang People's Hospital, Qingdao 266109, China.
Department of Nutriology, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Qingdao 266033, China.
Evid Based Complement Alternat Med. 2021 Nov 11;2021:3685213. doi: 10.1155/2021/3685213. eCollection 2021.
As a traditional Chinese medicine tonic, Buzhong Yiqi decoction has the effects of invigorating Qi and lifting Yang. In this study, the effects of Buzhong Yiqi Shenge decoction combined with THP bladder perfusion on postoperative efficacy in bladder cancer were investigated.
A total of 70 cases of bladder cancer patients were divided into the experimental group and control group according to the random number table method, with 35 cases in each group. The control group was treated with THP bladder perfusion. The experimental group was treated with Buzhong Yiqi Shenge decoction on the basis of the control group. The number of urine white blood cells, VEGF level, the incidence of adverse reactions, and KPS score were compared between the two groups before and after treatment.
After 3 and 6 months of therapy, the KPS score of the experimental group increased significantly compared with the control group. However, after 12 months of treatment, there was no difference in KPS scores between the two groups. Moreover, there was no significant variation in serum VEGF between two groups after 3 months of treatment. However, Buzhong Yiqi decoction notably reduced the level of VEGF after 6 months and 12 months. After 3 months, the urine white blood cell count was lower in the experimental group than in the control group. After 6 and 12 months, there was no difference in urine white blood cell count between the two groups. Furthermore, a total of 14 patients in two groups had reoccurrence after one year. Our results showed that there was no significant difference in postoperative recurrence rate between the experimental group and the control group. The occurrence rates of frequent and urgent urination, nausea/loss, and abnormal urine routine of appetite in the experimental group were significantly lower than those in the control group. But there was no difference in the occurrence rate of low heat, hematuria between the experimental group and the control group.
Buzhong Yiqi decoction combined with THP bladder perfusion has no advantage in the short-term recurrence rate of bladder cancer patients. However, Buzhong Yiqi decoction can alleviate the symptoms of adverse reactions and improve the quality of life of patients.
补中益气汤作为一种传统的中药滋补剂，具有益气升阳的功效。本研究探讨补中益气参芪汤联合吡柔比星膀胱灌注对膀胱癌术后疗效的影响。
将70例膀胱癌患者按随机数字表法分为实验组和对照组，每组35例。对照组采用吡柔比星膀胱灌注治疗。实验组在对照组的基础上加用补中益气参芪汤治疗。比较两组治疗前后尿白细胞计数、血管内皮生长因子（VEGF）水平、不良反应发生率及Karnofsky功能状态评分（KPS评分）。
治疗3个月和6个月后，实验组的KPS评分较对照组显著提高。然而，治疗12个月后，两组的KPS评分无差异。此外，治疗3个月后两组血清VEGF无显著变化。但补中益气汤在治疗6个月和12个月后显著降低了VEGF水平。治疗3个月后，实验组尿白细胞计数低于对照组。治疗6个月和12个月后，两组尿白细胞计数无差异。此外，两组共有14例患者在1年后复发。我们的结果显示，实验组和对照组术后复发率无显著差异。实验组尿频、尿急、恶心/食欲不振及尿常规异常的发生率显著低于对照组。但实验组与对照组低热、血尿的发生率无差异。
补中益气汤联合吡柔比星膀胱灌注对膀胱癌患者的短期复发率无优势。然而，补中益气汤可减轻不良反应症状，提高患者生活质量。
